Fortifying immunity: PLSCR1 picks battle against SARS-CoV-2

Minghua Li

doi:10.1016/j.chom.2023.08.014

Fortifying immunity: PLSCR1 picks battle against SARS-CoV-2

Cell Host Microbe. 2023 Sep 13;31(9):1417-1419. doi: 10.1016/j.chom.2023.08.014.

Author

Minghua Li¹

Affiliation

¹ Department of Pathology, University of Texas Medical Branch, Galveston, TX 77555, USA; Center for Biodefense and Emerging Infectious Diseases, University of Texas Medical Branch, Galveston, TX 77555, USA; Center for Tropical Diseases, University of Texas Medical Branch, Galveston, TX 77555, USA; Institute for Human Infections and Immunity, University of Texas Medical Branch, Galveston, TX 77555, USA. Electronic address: [email protected].

PMID: 37708846
DOI: 10.1016/j.chom.2023.08.014

Abstract

Interferons (IFNs) and interferon-stimulated genes (ISGs) are the major players in the host innate immunity against viral infection. In a recent Nature paper, Xu et al. identified phospholipid scramblase 1 (PLSCR1) as a novel ISG that restricts severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection by blocking virus-cell fusion.

MeSH terms

COVID-19*
Cell Fusion
Humans
Immunity, Innate
Interferons
Phospholipid Transfer Proteins
SARS-CoV-2*

Substances

Interferons
PLSCR1 protein, human
Phospholipid Transfer Proteins